We a support a national regulatory framework which protects Canadian patients, including addressing supply issues like drug shortages which put patients at risk.
BMC Positions:
Submission to the Government of Canada’s biomanufacturing consultation (March 2021)

Submission to the House of Commons Standing Committee on Finance (August 2020)

Submission to the House of Commons Standing Committee on Health (May 2020)

Letter to the Prime Minister Regarding COVID-19 and Drug Shortages (March 2020)

Submission to the Food and Drug Administration Regarding Drug Importation (March 2020)

Submission to the House of Commons Standing Committee on Health (March 2012)

Presentations:
Canada: The New Drugstore for America or Entering the Deep Freeze? – ISPOR 2021 – May 17, 2021